Cilostazol for Major Depressive Disorder After Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting: A Randomized, Double-Blind, Placebo-Controlled Trial
Research in Heart Yield and Translational Medicine (RHYTHM) · 08.09.2026
DOI: 10.18502/rhythm.v21i3.22566 ↗Kurz gefasst
Fachartikel in der Zeitschrift Research in Heart Yield and Translational Medicine (RHYTHM), online erschienen am 08.09.2026. Verfasst von Parisa Rajabi und 13 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Major depressive disorder (MDD) frequently occurs alongside coronary artery disease (CAD), worsening cardiovascular outcomes. Cilostazol is a phosphodiesterase 3 inhibitor used as an antiplatelet agent with potential antidepressant effects. This study evaluated the efficacy of cilostazol for treating depressive symptoms in participants with CAD.
Methods
This 6-week, double-blind, placebo-controlled clinical trial enrolled individuals with MDD and Hamilton Depression Rating Scale (HDRS) scores of 14 to 17 who had undergone percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG). Participants were randomly assigned to receive cilostazol (100 mg/d) or placebo. Outcomes included HDRS scores and adverse events.
Results
Baseline characteristics were similar between the groups (all P>.05). A significant time × treatment interaction effect on HDRS scores was observed (P=.037; partial η2=0.055). The cilostazol group showed greater reductions in HDRS scores through weeks 4 and 6 (P=.012 and P=.054, respectively). Adverse effects were not serious and were comparable between the groups (all P>.05).
Conclusion
Cilostazol was beneficial and safe for treating depressive symptoms in individuals who had recently undergone PCI or CABG. Further studies are needed to support broader clinical application
Zitieren
APA
Rajabi, P., Zanjani, F. T., Ershadmanesh, M., Mokhtari, F., Tabrizi, Z. H. F., Jameie, M., Natheghi, S., Mehrpouya, M., Hashempour, S., Sharafi, S. E., Vahidi, H., Shamabadi, A., Noorbala, A., & Akhondzadeh, S. (2026). Cilostazol for Major Depressive Disorder After Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting: A Randomized, Double-Blind, Placebo-Controlled Trial. Research in Heart Yield and Translational Medicine (RHYTHM). https://doi.org/10.18502/rhythm.v21i3.22566
Vancouver
Rajabi P, Zanjani FT, Ershadmanesh M, Mokhtari F, Tabrizi ZHF, Jameie M, et al. Cilostazol for Major Depressive Disorder After Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting: A Randomized, Double-Blind, Placebo-Controlled Trial. Research in Heart Yield and Translational Medicine (RHYTHM). 2026. doi:10.18502/rhythm.v21i3.22566
BibTeX
@article{Rajabi2026,
author = {Rajabi, Parisa and Zanjani, Fateme Taghavi and Ershadmanesh, Mohamadjavad and Mokhtari, Faezeh and Tabrizi, Zahra Haji Faraj and Jameie, Melika and Natheghi, Saeed and Mehrpouya, Maryam and Hashempour, Sara and Sharafi, Sayedeh Elham and Vahidi, Hamed and Shamabadi, Ahmad and Noorbala, Ahmad-Ali and Akhondzadeh, Shahin},
title = {Cilostazol for Major Depressive Disorder After Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting: A Randomized, Double-Blind, Placebo-Controlled Trial},
journal = {Research in Heart Yield and Translational Medicine (RHYTHM)},
year = {2026},
doi = {10.18502/rhythm.v21i3.22566}
}
EUVIMED